# AOD-9604 Research Guide: What the Science Says, and What It Doesn't

> Educational article from Veracue Labs. It summarizes published laboratory research and is not medical advice or instructions for use in people or animals.

- Page: https://veracuelabs.com/blog/aod-9604-research-guide
- Author: Veracue Research Team
- Published: 2026-10-28
- Last updated: 2026-10-27
- Topic: Metabolic research

AOD-9604 is a growth-hormone fragment studied for fat metabolism. Its own Phase 2B trial missed its primary endpoint, and FDA's 2024 panel voted against its compounding use.

Key points:
- AOD-9604 is a 16-residue fragment of human growth hormone, not full-length hGH, it doesn't bind the hGH receptor.
- Rodent studies show reduced weight gain and increased lipolysis; the compound's own human Phase 2B trial found no significant weight-loss difference versus placebo.
- On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 12-0 against adding AOD-9604 to the 503A Bulks List, agreeing with FDA staff's recommendation.
- AOD-9604 is named explicitly in WADA's Prohibited List (S2.2.3) and is banned at all times in competitive sport.
- This article does not cover dosing, reconstitution, or administration, see the live product listing for specifications, and the FAQ & Storage page for ordering questions.

AOD-9604 is a 16-amino-acid synthetic peptide built from the C-terminal end of human growth hormone, engineered in the 1990s to isolate hGH's fat-metabolizing activity from its growth-promoting and blood-sugar-raising effects. It went through human Phase I and Phase II testing for obesity in the 2000s and was never approved as a drug for that or any other indication. On December 4, 2024, the FDA's Pharmacy Compounding Advisory Committee voted unanimously against adding it to the 503A Bulks List (FDA briefing document), and it is named explicitly on the 2026 WADA Prohibited List. This guide separates what the preclinical and human research actually measured from what regulators have, and haven't, decided. Veracue Labs supplies AOD-9604 strictly for laboratory research use.

### What Is AOD-9604?

AOD-9604 (sequence YLRIVQCRSVEGSCGF, CAS 221231-10-3, also referenced as LAT8881) corresponds to residues 177, 191 of human growth hormone, with an added N-terminal tyrosine and a Cys7, Cys14 disulfide bridge holding the back half into a small loop. That region of hGH had been identified as its "lipolytic domain", the part of the molecule most associated with fat breakdown rather than growth-plate signaling, and AOD-9604 was engineered specifically to reproduce that activity on its own. Its chemical identity and its origin as an hGH-fragment analog are settled; it's also established that it doesn't bind the hGH receptor the way intact hGH does. What isn't settled is whether that activity translates into a clinically meaningful treatment effect in humans, current regulatory review says the obesity data haven't met that bar.

### Where Did AOD-9604 Come From?

AOD-9604 was developed by researchers at Monash University in Australia and commercialized by Metabolic Pharmaceuticals Ltd., which took the compound through Phase I and Phase II human trials for obesity in the early-to-mid 2000s (Wilding, 2004). The research logic was straightforward: full-length hGH does reduce fat mass with chronic use, but it also raises blood glucose and can affect insulin sensitivity. If the fat-metabolizing effect could be separated from the rest of the molecule, the thinking went, you might get the metabolic benefit without the glucose liability, the same rationale that later shaped interest in other growth-hormone-axis compounds like GHRP-6. That hypothesis is what AOD-9604's entire development program was built to test. The rationale behind it is well-defined; whether it actually panned out in humans, per the regulatory record below, is a separate question.

### What Is AOD-9604's Proposed Mechanism of Action?

In obese and lean mice, chronic treatment with either full-length hGH or AOD-9604 reduced body-weight gain and increased fat oxidation and lipolysis (plasma glycerol), but AOD-9604 didn't compete for the hGH receptor and didn't stimulate hGH-receptor-mediated cell proliferation the way hGH itself did (Heffernan et al., 2001a). A follow-up study from the same group found that both hGH and AOD-9604 increased expression of beta-3 adrenergic receptors (β3-AR), the principal lipolytic receptor on fat cells, and that in β3-AR knockout mice, chronic AOD-9604 treatment failed to reproduce the weight and lipolysis effects seen in normal mice, though an acute effect on energy expenditure and fat oxidation still occurred (Heffernan et al., 2001b). That's a mouse-model finding. Nobody has shown the same pathway operating in human fat cells, so "activates the beta-3 pathway" should stay scoped to the species it was actually tested in.

Compound | What it is | Binds the hGH receptor? | Regulatory status
Human growth hormone (hGH) | Full 191-residue hormone | Yes | FDA-approved for specific indications
AOD-9604 | 16-residue C-terminal fragment, Tyr-hGH 177-191 | No | No FDA-approved indication; 2024 PCAC voted 12-0 against 503A inclusion
HGH Fragment 176-191 | Native, unmodified C-terminal fragment | No | Related but chemically distinct from AOD-9604; named separately on the WADA list

### What Do Animal Studies Show?

Rodent data are the strongest part of the AOD-9604 evidence base. Obese Zucker rats given daily oral AOD-9604 for 19 days showed more than 50% less body-weight gain than untreated controls, alongside increased adipose-tissue lipolytic activity and no adverse effect on insulin sensitivity under euglycemic clamp testing, in contrast to chronic intact-hGH treatment (Ng et al., 2000). Separately, intra-articular AOD-9604 was tested in a rabbit knee osteoarthritis model, where combining it with hyaluronic acid outperformed either agent alone on cartilage-degeneration scoring, a 2015 finding relevant to a different, non-metabolic research direction for the same molecule.

### What Did AOD-9604's Human Trials Find?

Phase I/IIa human trials were underway by early 2002 (Wilding, 2004), and a Phase IIb obesity trial followed under Metabolic Pharmaceuticals' sponsorship. Per FDA's 2024 advisory-committee briefing document, which reports the sponsor's own 2007 disclosure, the Phase 2B trial found "not a significant difference in the primary endpoint of weight loss between placebo and AOD-9604," and the sponsor itself announced the results "do not support the commercial viability of the drug." That trial doesn't appear to have been published in the medical literature, so the only available account of the Phase 2B outcome is the sponsor's 2007 announcement, relayed secondhand through an FDA document, not an independently peer-reviewed report.

FDA's 2024 briefing document also raised compound-level concerns independent of the efficacy question: it describes both the free-base and acetate forms as "not physically and chemically well characterized," says FDA "cannot rule out the potential for immunogenicity" from impurities and peptide-related aggregates, and reports that genotoxicity studies "induced equivocal mutagenic signals" in several assays. None of this is dosing or safety guidance, it's a summary of what FDA's own review flagged as unresolved.

### What Are the Gaps in the Current Evidence?

No AOD-9604 product has FDA approval for any indication, and the human trial program that would be required to establish safety and efficacy was never completed to a standard regulators found convincing. Most of the mechanistic and efficacy literature is from 2000, 2004; newer work, like a 2015 rabbit osteoarthritis study and two 2026 review articles, is largely adjacent rather than confirmatory, it discusses AOD-9604 within broader peptide-safety and regulatory contexts, not new efficacy data for the original obesity hypothesis. Readers comparing AOD-9604 against other metabolic-research compounds, like GLP-3RTA or NAD+ and AHK-Cu, should weigh each compound's own evidence base independently rather than assume parity across the category.

### Is AOD-9604 FDA-Approved, or Banned in Sport?

AOD-9604 has no FDA-approved indication, for weight loss or anything else. Its U.S. compounding-law status has moved through several distinct stages. FDA's own bulk-drug-substances page currently places AOD-9604 under "Bulk drug substances nominated but withdrawn," and separately notes FDA "has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear." Ahead of a December 4, 2024 Pharmacy Compounding Advisory Committee meeting, FDA staff concluded that "the evaluation criteria weigh against placing" AOD-9604 on the 503A Bulks List, citing a "lack of evidence to support the effectiveness of AOD-9604" alongside the characterization and safety concerns above. The committee's approved minutes confirm what happened next: asked directly whether AOD-9604 (free base) and AOD-9604 acetate should be placed on the list, the committee voted unanimously against it, 0 in favor to 12 opposed, with no recorded discussion on that question. That's a confirmed committee recommendation, not yet a final agency rule, no later final determination was located as of this writing. Separately, and independently of any U.S. compounding question, AOD-9604 is named explicitly in WADA's 2026 Prohibited List under section S2.2.3, "Growth hormone, its analogues and fragments", prohibited at all times, in and out of competition. Analytical chemists have separately published validated urine-detection methods and identified a stable serum metabolite for doping-control screening (Cox et al., 2014).

### Is AOD-9604 the Same as HGH Fragment 176-191?

Two mix-ups come up constantly with AOD-9604, and both change how you should read a study. First: it isn't full-length human growth hormone, it doesn't bind the hGH receptor and doesn't carry hGH's growth-promoting or glucose-raising pharmacology; it was built to strip those effects out. For context on a growth-hormone-axis compound that is FDA-approved, see tesamorelin, a GHRH analog approved as Egrifta, a useful regulatory contrast to AOD-9604's unapproved status. Second: AOD-9604 isn't the same molecule as "HGH Fragment 176-191," a related but chemically distinct compound some vendors use interchangeably with it. AOD-9604 is a modified analog (Tyr-hGH 177-191, with the added N-terminal tyrosine and its own CAS number); HGH Fragment 176-191 is the unmodified native sequence. Evidence generated on one shouldn't be read as evidence for the other. WADA's own 2026 list treats them as two separate named examples within the same fragment class, independent confirmation that regulators track them as distinct substances, not synonyms.

### How Well-Documented Is AOD-9604, Really?

Because AOD-9604 has an active, recent regulatory record and a long analytical-chemistry literature, it's better documented at the level of chemical identity and compound-specific regulatory history than many comparable research peptides. A well-characterized identity isn't the same thing as established treatment efficacy, though, for AOD-9604, the latter is explicitly not established per FDA's own evaluation above. For lot-specific purity and identity documentation, see Veracue's Certificates of Analysis; for general ordering and storage questions not covered here, see the FAQ & Storage page. This article doesn't cover dosing, reconstitution, or self-administration, it's written for people evaluating the research record, not using the compound.

Questions and answers:

Q: What is AOD-9604?
A: AOD-9604 is a synthetic 16-amino-acid peptide built from the C-terminal end of human growth hormone (residues 177, 191), with an added N-terminal tyrosine and a Cys7, Cys14 disulfide bond. It was designed to isolate hGH's fat-metabolizing activity from its growth-promoting effects. It is sold for research use only and has no FDA-approved indication.

Q: What is AOD-9604 being investigated for?
A: Research has focused on lipolysis (fat breakdown) and obesity-related metabolic effects, reflecting the hypothesis that hGH's fat-metabolizing activity could be separated from its glucose-raising effects. Later, unrelated preclinical work has also examined intra-articular use in an osteoarthritis model.

Q: How does AOD-9604 differ from full-length human growth hormone?
A: AOD-9604 is a 16-residue fragment, not the full 191-residue hormone. Preclinical research found it does not bind the hGH receptor and does not drive hGH-receptor-mediated cell proliferation, unlike intact hGH.

Q: What is the proposed mechanism of AOD-9604?
A: Rodent studies link AOD-9604's effects to increased beta-3 adrenergic receptor expression on fat cells rather than direct hGH-receptor signaling. In beta-3-receptor knockout mice, the chronic weight and lipolysis effect did not occur, though an acute fat-oxidation effect persisted, meaning the mechanism is not fully resolved even in animal models.

Q: What does scientific research say about AOD-9604 and fat metabolism?
A: Rodent studies (obese mice and Zucker rats) show reduced weight gain and increased lipolytic markers with chronic AOD-9604 treatment, without the insulin-sensitivity impairment seen with intact hGH. These are animal findings and are not equivalent to a demonstrated human weight-loss effect.

Q: What human research has been conducted on AOD-9604?
A: AOD-9604 went through Phase I and Phase II human trials for obesity in the early-to-mid 2000s under its original sponsor, Metabolic Pharmaceuticals. Per FDA's 2024 regulatory briefing document, the sponsor itself announced in 2007 that the Phase 2B trial found no significant weight-loss difference versus placebo. That trial does not appear to have been published in the medical literature.

Q: Are the proposed effects of AOD-9604 established in humans?
A: No. The strongest supporting data are preclinical (rodent). The compound's own human Phase 2B obesity trial found no significant weight-loss difference versus placebo, and no indication has received FDA approval.

Q: What are the major limitations of current AOD-9604 research?
A: The human efficacy signal did not replicate the rodent findings; most primary literature is from 2000, 2004 with limited newer efficacy data; and FDA's 2024 review separately raised concerns about the substance's chemical characterization, impurity profile, and nonclinical safety signals.

Q: Is AOD-9604 the same as HGH Fragment 176-191?
A: No. AOD-9604 (Tyr-hGH 177-191, CAS 221231-10-3) has an added N-terminal tyrosine not present in the native HGH Fragment 176-191 sequence. They share an origin in the same region of hGH but are chemically distinct compounds.

Q: Is AOD-9604 FDA-approved for weight loss?
A: No. AOD-9604 has no FDA-approved indication for weight loss or any other use. On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 12-0, with no abstentions, against adding it to the 503A Bulks List, agreeing with FDA staff's prior recommendation. That is a confirmed committee vote, not yet a final FDA rule.

Q: Is AOD-9604 prohibited in competitive sport?
A: Yes. WADA's 2026 Prohibited List names AOD-9604 directly, under section S2.2.3 ('Growth hormone, its analogues and fragments'), as an example growth hormone fragment, prohibited at all times, in- and out-of-competition.

Q: What does Research Use Only mean for this product?
A: Research Use Only means the product is sold strictly for laboratory and research purposes, not as a drug, dietary supplement, or product for human or veterinary use. Veracue Labs does not provide dosing, reconstitution, or administration guidance.

References:
1. Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436-40. (https://pubmed.ncbi.nlm.nih.gov/15134286/)
2. Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-9. (https://doi.org/10.1038/sj.ijo.0801740)
3. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. (https://doi.org/10.1210/endo.142.12.8522)
4. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. (https://doi.org/10.1159/000053183)
5. Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2014;7(1):31-8. (https://doi.org/10.1002/dta.1715)
6. U.S. Food and Drug Administration. Briefing Document for the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting: AOD-9604-Related Bulk Drug Substances. (https://www.fda.gov/media/183584/download)
7. U.S. Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024 (approved February 21, 2025). AOD-9604 vote: Yes 0, No 12, Abstain 0. (https://www.fda.gov/media/185642/download)
8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, AOD-9604. (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)
9. World Anti-Doping Agency. The 2026 Prohibited List, AOD-9604 named under S2.2.3, Growth Hormone and Its Analogues and Fragments. (https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)

More from Veracue Labs: https://veracuelabs.com/llms.txt